Ilse Andrea Moreno-Arquieta

Dr. Ilse Andrea Moreno-Arquieta

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Rheumatology International
Verified
Journal Article
Open access
PDF file
JEJorge Antonio Esquivel-Valerio
Jorge Antonio Esquivel-Valerio
CSCassandra Michele Skinner-Taylor
Cassandra Michele Skinner-Taylor
IMIlse Andrea Moreno-Arquieta
Ilse Andrea Moreno-Arquieta
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza
GGGisela Garcia-Arellano
Gisela Garcia-Arellano
DGDioncio Angel Galarza-Delgado
Dioncio Angel Galarza-Delgado
Data regarding COVID-19 vaccine efficacy and adverse events (AE) in patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently although these mostly include the mRNA vaccines (Pfizer-BioNTech and Moderna) and the ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca). This research aimed to study the prevalence of AE presented with six different SARS-CoV-2 vaccines {ChadOX1 nCoV-19 (AZD1222), Ad5-nCoV2, Ad26.COV2.S, mRNA-1273, BNT162b2, and CoronaVac} in Mexican patients with AIIRD. We performed a cross-sectional study about vaccine history. Two hundred and twenty five consecutive patients were recruited, mean age was 50.7 years and the majority (n = 213; 94.6%) were females. One hundred and seven (47.5%) received BNT162b2 mRNA, 34 (15.1%) Ad5-nCoV, 29 (12.8%) mRNA-1273, 28 (12.4%) ChAdOX1 nCoV-19 (AZD1222), 22 (9.7%) CoronaVac and 5 (2.2%) Ad26.COV2.S. The vaccines that had the most AE proportionally to the number of patients vaccinated were Janssen (5; 100%) followed by Pfizer-BioNTEch (86; 80%) and CanSinoBIO (27; 79.4%). Localized pain was the most frequent (158; 70.2%) AE. Fatigue (78; 34.7%), headache (69; 30.6%) and muscle ache (66; 29.3%) were the most common systemic symptoms. No serious AE that required medical attention or hospitalization were reported. The current results support the safety of different COVID-19 vaccines in patients with AIIRD. This information can help fight vaccine hesitancy in this population.

21 February 2021 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
IMIlse Andrea Moreno-Arquieta
Ilse Andrea Moreno-Arquieta
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza
JEJorge Antonio Esquivel-Valerio
Jorge Antonio Esquivel-Valerio
JRJanett Riega-Torres
Janett Riega-Torres
ACAdrian Cuellar-Barboza
Adrian Cuellar-Barboza
DGDionicio Angel Galarza-Delgado
Dionicio Angel Galarza-Delgado
Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. We performed a MEDLINE search using the keywords ‘eosinophilic fasciitis’, ‘Shulman syndrome’, ‘mycophenolic acid’, or ‘mofetil mycophenolate’, and found 8 articles with 27 cases in which MMF or MPA was used. Twenty-nine cases were reviewed (2 reported herein and 27 from the literature search); all patients received a combination of systemic corticosteroids and MMF. MMF/MPA were given as a steroid-sparing agent in 27 (93.1%), in 1 (3.4%) as adjunctive therapy with other immunosuppressants, and in one, as monotherapy 1 (3.4%). Nineteen had a complete response, 6, a partial response, and 2 were unresponsive to diverse immunomodulators; in 2 cases, the outcome was not reported. MMF and MPA show promising therapeutic results and could be a treatment option to reduce corticosteroid related side effects.


15 March 2024 in Reumatología Clínica (English Edition)
Verified
Journal Article
Closed access
GSGrisel Guadalupe Sánchez-Mendieta
Grisel Guadalupe Sánchez-Mendieta
DVDavid Vega-Morales
David Vega-Morales
MVMiguel Ángel Villarreal-Alarcón
Miguel Ángel Villarreal-Alarcón
JCJesús Eduardo Compean-Villegas
Jesús Eduardo Compean-Villegas
IMIlse Andrea Moreno-Arquieta
Ilse Andrea Moreno-Arquieta
DGDionicio Ángel Galarza-Delgado
Dionicio Ángel Galarza-Delgado

18 August 2026 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
IMIlse Andrea Moreno-Arquieta
Ilse Andrea Moreno-Arquieta
HRHéctor Teodoro Rios‐Bazaldua
Héctor Teodoro Rios‐Bazaldua
RGRoger Adrián González‐Ramírez
Roger Adrián González‐Ramírez
GSGabriel Salerni
Gabriel Salerni
EAErika Stephania Alvarado‐Arana
Erika Stephania Alvarado‐Arana
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza

30 April 2020 in Trauma Cases and Reviews
Verified
Journal Article
Open access
MPMolina Carlos Pacheco
Molina Carlos Pacheco
MVMiranda Héctor Vergara
Miranda Héctor Vergara
LDLeón Oscar Rene García de
León Oscar Rene García de
IMIlse Andrea Moreno-Arquieta
Ilse Andrea Moreno-Arquieta
MMMaldonado Gerardo Enrique Muñoz
Maldonado Gerardo Enrique Muñoz
Penetrating Cardiac Injury (PCI) is a rare but life-threatening clinical condition in trauma patients. According to previous reports, incidence of PCI admissions to trauma centers has been reported to be of 0.16%, with heterogeneous survival rates being as low as 3% and as high as 84%.